The Times Australia
Google AI
PR Newswire

.

Zymo Research Obtains CE IVD Mark for its Quick SARS-CoV-2 Multiplex Kit-PR Newswire APAC

Zymo Research Obtains CE IVD Mark for its Quick SARS-CoV-2 Multiplex Kit-PR Newswire APAC

Low cost, high-sensitivity diagnostic test for COVID-19 detection

IRVINE, Calif., Nov. 10, 2020 /PRNewswire/ -- Zymo Research announced today that it obtained a CE IVD mark for the Quick SARS-CoV-2 Multiplex Kit in compliance with the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. The Quick SARS-CoV-2 Multiplex Kit[1] is a real-time reverse transcription PCR (RT-PCR) test used for the qualitative detection of nucleic acids from SARS-CoV-2 (the virus that causes COVID-19) in upper and lower respiratory specimens taken from patients whose healthcare providers suspect have contracted COVID-19.

Zymo Research obtained the CE IVD mark for its Quick SARS-CoV-2 Multiplex Kit. Zymo Research obtained the CE IVD mark for its Quick SARS-CoV-2 Multiplex Kit.

The Quick SARS-CoV-2 Multiplex Kit has a limit of detection (LoD) of 10-virus copies/reaction and up to 382 samples can be analyzed for each RT-PCR run. This high performance, combined with increased throughput, competitive pricing, and a widespread distribution network, makes this test among the best on the market.* The kit is ideal for clinical diagnostic labs that currently offer or want to offer COVID-19 testing including hospitals, universities, research centers, as well as laboratories that perform environmental surveillance for SARS-CoV-2.

The kit is easy to use in any lab equipped with RT-PCR instrumentation that is capable of detecting HEX (or VIC) and Quasar 670 (or Cy5) fluorophores. It comes in multiple formats (100-, 1,000-, or 10,000-test quantities), which make it amenable for use in small or large laboratories. With a strong international distribution network and a high production capacity, Zymo Research is capable of meeting the high-volume reagent demands of laboratories around the globe.

"With over 46 million** COVID-19 cases reported worldwide, our goal is to help stop the spread of SARS-CoV-2 by enabling increased testing," said Dr. Paolo Piatti, Senior Scientist at Zymo Research. "The CE IVD mark, along with the competitive pricing, makes this high-quality product readily accessible to laboratories and ultimately expands the availability of COVID-19 testing to many more facilities throughout the world."

For more information about Zymo Research's Quick SARS-CoV-2 Multiplex Kit and workflow, please visit their website[2] or contact them via email at covid19requests@zymoresearch.com[3].

About Zymo Research Corp.Zymo Research is a privately owned company that has been serving the scientific and diagnostics community with state-of-the-art molecular biology tools since 1994. "The Beauty of Science is to Make Things Simple" is their motto, reflected in all of their products, from epigenetics to DNA/RNA purification technologies. Historically recognized as the leader in epigenetics, Zymo Research is breaking boundaries with novel solutions for sample collection, microbiomic measurements, diagnostic devices, and NGS technologies that are high quality and simple to use. Follow Zymo Research on Facebook[4], LinkedIn[5], Twitter[6], and Instagram[7].

References* https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data **https://www.statista.com/statistics/1087466/covid19-cases-recoveries-deaths-worldwide/[8][9]

Photo - https://mma.prnasia.com/media2/1330735/zymo_research_corp_quick_sars_cov_2_multiplex_kit_ce_ivd.jpg?p=medium600[10] Logo - https://mma.prnasia.com/media2/364743/Zymo_Research_Corp_Logo.jpg?p=medium600[11]

Source: Zymo Research Corp.

Read more https://www.prnasia.com/story/archive/3186131_AE86131_0

Business Times

Mint Payments partners with Zip Co to add flexible payment option…

Mint Payments, Australia's leading travel payments specialist, today announced a partnership with Zip Co (ASX: ZIP), a digi...

When Holiday Small Talk Hurts Inclusion at Work

Dr. Tatiana Andreeva, Associate Professor in Management and Organisational Behaviour, Maynooth University, Ireland, tatia...

Reflections invests almost $1 million in Tumut River park to boos…

Reflections Holidays, the largest adventure holiday park group in New South Wales, has launched four tiny homes at its Tu...

The Times Features

I’m heading overseas. Do I really need travel vaccines?

Australia is in its busiest month[1] for short-term overseas travel. And there are so many thi...

Mint Payments partners with Zip Co to add flexible payment options for travel merchants

Mint Payments, Australia's leading travel payments specialist, today announced a partnership with ...

When Holiday Small Talk Hurts Inclusion at Work

Dr. Tatiana Andreeva, Associate Professor in Management and Organisational Behaviour, Maynooth U...

Human Rights Day: The Right to Shelter Isn’t Optional

It is World Human Rights Day this week. Across Australia, politicians read declarations and clai...

In awkward timing, government ends energy rebate as it defends Wells’ spendathon

There are two glaring lessons for politicians from the Anika Wells’ entitlements affair. First...

Australia’s Coffee Culture Faces an Afternoon Rethink as New Research Reveals a Surprising Blind Spot

Australia’s celebrated coffee culture may be world‑class in the morning, but new research* sugge...

Reflections invests almost $1 million in Tumut River park to boost regional tourism

Reflections Holidays, the largest adventure holiday park group in New South Wales, has launched ...

Groundbreaking Trial: Fish Oil Slashes Heart Complications in Dialysis Patients

A significant development for patients undergoing dialysis for kidney failure—a group with an except...

Worried after sunscreen recalls? Here’s how to choose a safe one

Most of us know sunscreen is a key way[1] to protect areas of our skin not easily covered by c...